Publication | Open Access

Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097)

National Cancer InstituteAzd 2171MedicinePharmacologyPhase Ii StudyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyLung Cancer